NEW YORK CITY, NY / ACCESS Newswire / October 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Protalix BioTherapeutics, Inc. ("Protalix" or "the Company") (NYSE:PLX). Investors who purchased Protalix securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PLX.

Investigation Details

On October 17, 2025, Protalix and Chiesi Global Rare Diseases, Protalix's partner in "the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system", issued a press release "acknowledging that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a negative opinion on the request to approve the dosing regimen of 2 mg/kg body weight infused every 4 weeks (E4W) for Elfabrio (pegunigalsidase alfa, in addition to the currently approved dosing regimen of 1 mg/kg body weight infused every 2 weeks (E2W)." Following this news, Protalix's stock price fell $0.54 per share, or 22.5%, to close at $1.86 per share on October 17, 2025.

What's Next?

If you are aware of any facts relating to this investigation or purchased Protalix securities, you can assist this investigation by visiting the firm's site: bgandg.com/PLX. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

View the original press release on ACCESS Newswire